Published in Head Neck on June 01, 2008
Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer (2010) 1.59
Current aspects on oral squamous cell carcinoma. Open Dent J (2012) 1.47
Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg (2015) 1.39
Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer (2011) 1.07
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) (2010) 1.03
Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature. Oncotarget (2015) 0.93
Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol Cancer Ther (2011) 0.89
Optical molecular imaging of multiple biomarkers of epithelial neoplasia: epidermal growth factor receptor expression and metabolic activity in oral mucosa. Transl Oncol (2012) 0.87
Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. J Exp Clin Cancer Res (2010) 0.86
The Apoptotic Effect of the Hexane Extract of Rheum undulatum L. in Oral Cancer Cells through the Down-regulation of Specificity Protein 1 and Survivin. Lab Anim Res (2011) 0.84
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med (2014) 0.82
Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS One (2009) 0.81
Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition. Oncol Lett (2015) 0.80
CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma. Dent Res J (Isfahan) (2015) 0.77
Expression of Prostanoid EP3 Receptors in Oral Squamous Epithelium and Oral Squamous Cell Carcinoma. Patholog Res Int (2015) 0.75
Molecular Classification of Oral Squamous Cell Carcinoma. J Clin Diagn Res (2016) 0.75
STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma. Int J Oncol (2016) 0.75
Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas. J Oncol (2009) 0.75
Sex hormones in gender-specific risk for head and neck cancer: A review. J Int Soc Prev Community Dent (2014) 0.75
Prognostic value of proliferating cell nuclear antigen in parotid gland cancer. Eur Arch Otorhinolaryngol (2011) 0.75
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
The future of the TNM staging system in laryngeal cancer: time for a debate? Eur Arch Otorhinolaryngol (2008) 2.58
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Paragangliomas of the head and neck. Oral Oncol (2004) 2.47
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev (2007) 2.31
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res (2007) 2.21
Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope (2014) 2.21
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck (2011) 1.97
CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res (2010) 1.97
Neuroendocrine neoplasms of the larynx: an overview. Head Neck (2009) 1.92
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. Oral Oncol (2006) 1.70
Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2003) 1.68
Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg (2008) 1.68
Helix-loop-helix proteins in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia (2003) 1.57
Thyroglossal duct cyst: personal experience and literature review. Auris Nasus Larynx (2007) 1.57
Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol (2012) 1.55
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab (2007) 1.53
Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg (2004) 1.53
Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo. ACS Nano (2012) 1.49
Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol (2010) 1.48
LANTCET: elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles. Nanomedicine (Lond) (2008) 1.45
Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer (2004) 1.44
Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer (2004) 1.43
Sinonasal tumors: a clinicopathologic update of selected tumors. Eur Arch Otorhinolaryngol (2012) 1.43
High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43
An outline of the history of head and neck oncology. Oral Oncol (2007) 1.42
Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer (2003) 1.41
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol (2010) 1.40
Do pathologic and molecular analyses of neck dissection specimens justify the preservation of level IV for laryngeal squamous carcinoma with clinically negative neck? J Am Coll Surg (2005) 1.39
Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol (2002) 1.38
Xenograft models of head and neck cancers. Head Neck Oncol (2009) 1.37
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
Aspergillosis--and a misleading sensitivity result. Lancet (2007) 1.36
Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck (2010) 1.34
Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck (2010) 1.34
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer (2003) 1.33
Management of sarcomas of the head and neck in adults. Oral Oncol (2003) 1.31
Evidence-based review of treatment options for patients with glottic cancer. Head Neck (2011) 1.30
Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 1.29
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res (2010) 1.29
The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg (2003) 1.28
Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst (2007) 1.27
Neck disease and distant metastases. Oral Oncol (2003) 1.27
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther (2007) 1.26
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res (2004) 1.26
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res (2004) 1.26
Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol (2010) 1.26
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res (2007) 1.24
An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res (2005) 1.23
A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis (2011) 1.22
Human papillomavirus infections in laryngeal cancer. Head Neck (2011) 1.22
Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res (2003) 1.21
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res (2011) 1.21
Akt activation correlates with adverse outcome in tongue cancer. Cancer (2005) 1.20
Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck (2010) 1.20
Surgical margins in head and neck cancer: a contemporary review. Head Neck (2012) 1.19
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res (2006) 1.18
Esthesioneuroblastoma and cervical lymph node metastases: clinical and therapeutic implications. Acta Otolaryngol (2002) 1.16
Management of nasal bone fractures. Am J Otolaryngol (2005) 1.16
Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. Head Neck (2003) 1.15
Cyclin G2 dysregulation in human oral cancer. Cancer Res (2004) 1.15
Neck dissection: then and now. Auris Nasus Larynx (2006) 1.14